Collegium Pharmaceutical Reports Quarterly Results for June 30, 2026

What Happened
Collegium Pharmaceutical, Inc. announced its financial results for the quarterly period ended June 30, 2026 by issuing a press release on August 6, 2026 (reported under Item 2.02). The company also released an earnings presentation on the same date (reported under Item 7.01). Both the press release and the presentation are attached to the 8‑K as Exhibits 99.1 and 99.2 and are being furnished, not filed. The filing is signed by Colleen Tupper, Executive Vice President and Chief Financial Officer.

Key Details

• Date of disclosure: August 6, 2026.
• Reporting period: quarterly period ended June 30, 2026.
• Exhibits furnished: 99.1 (Press Release) and 99.2 (Earnings Presentation).
• Items reported: Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).

Why It Matters
This 8‑K signals that Collegium has publicly disclosed its latest quarterly results and provided an investor presentation; those documents will contain the specifics investors care about (revenue, earnings, cash flow, and any commentary on trends or guidance). Because the materials are furnished (not filed), they are disclosures meant for broad public distribution; investors should review the attached press release and presentation for actual financial figures and management commentary before making investment decisions.